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Emerging  evidence  indicates  that  treatment  context  profoundly  affects  psychopharmacological  interven-
tions. We  review  the  evidence  for the interaction  between  drug  application  and  the context  in which  the
drug  is given  both  in  human  and  animal  research.  We  found  evidence  for this  interaction  in  the  placebo
response  in  clinical  trials,  in  our  evolving  knowledge  of pharmacological  and  environmental  effects  on
neural  plasticity,  and  in animal  studies  analyzing  environmental  inﬂuences  on psychotropic  drug  effects.
Experimental  placebo  research  has  revealed  neurobiological  trajectories  of  mechanisms  such  as  patients’
treatment  expectations  and  prior treatment  experiences.  Animal  research  conﬁrmed  that  “enriched  envi-
ronments”  support  positive  drug  effects,  while  unfavorable  environments  (low  sensory  stimulation,  loweuroplasticity rates of  social  contacts)  can  even  reverse  the intended  treatment  outcome.  Finally  we provide  recommen-
dations  for  context  conditions  under  which  psychotropic  drugs  should  be applied.  Drug  action  should  be
steered  by  positive  expectations,  physical  activity,  and  helpful  social  and  physical  environmental  stim-
ulation.  Future  drug  trials  should  focus  on  fully  controlling  and  optimizing  such  drug  ×  environment
interactions  to improve  trial sensitivity  and  treatment  outcome.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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. Introduction
Treatment responses to psychopharmacological interventions
re highly variable. The factors contributing to variations in treat-
ent success beyond the drug treatment itself are poorly controlled
n clinical trials. Together with strong placebo responses, this has
ontributed to low trial sensitivity, and a decline in the develop-
ent of new therapeutic drugs. We  summarize how contextual
actors and placebo mechanisms contribute to the efﬁciency of
rug interventions via interactions with neurobiological trajecto-
ies of drug effects. Contextual factors represent environmental
timulation and include physical stimuli, effects of physical activ-
ty, social networks and social interactions (including therapeutic
elationships). Placebo mechanisms encompass features of the per-
on and/or the person-environment interaction that contribute
o drug efﬁciency beyond the neurochemical drug effect itself.
ypical examples of placebo mechanisms are expectations about
reatment success, expectations about side effects (nocebo effects),
ttributions of mental and bodily changes to drug intake, and
re-experiences with drug treatments via associative learning pro-
esses. This paper will summarize evidence for the interaction of
rug effects, placebo mechanisms, and contextual factors on the
evel of brain plasticity in depression and schizophrenia (see Fig. 1).
ased on these considerations we propose new recommendations
o optimize drug × environment interactions, and maximize treat-
ent effects.
. The evidence for psychopharmacological drugs: good,
ut not good enough?
Cochrane meta-analyses have shown that antidepressants and
ntipsychotics lead to reductions of corresponding affective or cog-
itive symptoms of depression and schizophrenia (Adams et al.,
013; Arroll et al., 2009; Leucht et al., 2012a). Moreover, discontin-
ation of drug treatment is frequently associated with relapse and
ecurrence (Leucht et al., 2012b), which is typically interpreted as
ndicating the need for continued pharmacological interventions.
ased on this strong evidence in particular for short-term effects,
ig. 1. The interaction of environmental and placebo mechanisms with psychotropic dru
rain  functions is in continuous interaction with brain plasticity stimulated by environm
solate direct inﬂuences of the drug on brain functions (see (1)), it is hypothesized that fut
timulated brain plasticity.avioral Reviews 60 (2016) 51–64
medical guidelines clearly recommend the use of these drugs for
depression and psychosis.
However, even the most positive summaries about the effec-
tiveness of antidepressants and antipsychotics reveal only small to
moderate differences in favor of drugs versus placebos (see below).
Placebo responses are high and sometimes they even achieve the
same level as drug responses (Barber et al., 2012). The advantage of
psychopharmacological drugs over placebos is even smaller when
compared to “active” placebos instead of the standard inert placebo
pill (Moncrieff et al., 2004). The experience of drug-speciﬁc side
effects or onset effects can further challenge trial validity. These
sensations can trigger improvements based on expectation and
other placebo mechanisms rather than through speciﬁc drug effects
(Rief and Glombiewski, 2012).
One problem in the evaluation of psychotropic drugs is the
diffuse boundary of the clinical target conditions, which further
reduces assay sensitivity. Depression, schizophrenia and other
mental disorders are not distinct entities, but typically overlap. The
majority of patients with major depression also fulﬁll the criteria for
another mental disorder (Blazer et al., 1994). Many patients suffer
from complex interactions between mental disorders with phys-
ical conditions, and the risk of diabetes, cardiovascular diseases,
a.o., is substantially increased in psychiatric patients (De Hert et al.,
2009). Accepting this heterogeneity in clinical trials leads to low
trial sensitivity because of large variance, while excluding comor-
bid patients leads to artiﬁcial selections that cannot be generalized
to clinical care samples.
The evaluation of the evidence for psychopharmacological
treatments is further complicated by publication bias. Few meta-
analyses have attempted to integrate non-published trials in
the overall evaluation of antidepressants, and reported sub-
stantial reductions of overall effect size compared to analyses
solely based on published trials (Eyding et al., 2010; Turner
et al., 2008). An increasingly positive bias in published tri-
als is also seen in increasing effect sizes of placebo groups
over the last 20 years in antidepressant (Rief et al., 2009a;
Walsh et al., 2002) and in antipsychotic trials (Rutherford et al.,
2014).
g treatments on adaptive brain functioning. The inﬂuence of psychotropic drugs on
ental inﬂuences and placebo mechanisms. While traditional developments tried to
ure developments should focus on improving the interaction with environmentally
W.  Rief et al. / Neuroscience and Biobeh
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in psychopharmacological trials due to ethical reasons (Krogsboll
et al., 2009; Laughren, 2001).
Only three trials were identiﬁed that directly compared antide-
pressants with placebo and a no-treatment control group or a
Box 1: Implications of natural course and placebo
responses for clinical treatment decision
Research on the results on natural course of mental disor-
ders and placebo effects motivate a rethinking of treatment
decisions (see Table 1). Longitudinal investigations reveal that
about half of the patients in primary care and the general pop-
ulation suffering from depression recover independently of
treatment type (Steinert et al., 2014). Under speciﬁc circum-
stances, antidepressants seem to even block improvements
in mental disorders (Andersson et al., 2015). Some people
improve under placebo treatments, and the beneﬁt-risk-ratio
could be better for them under placebo than drug treatment.
For example, using mathematical modeling of treatment tra-
jectories with antidepressants, about 20% in the drug group
treated with duloxetine had worse trajectories than com-
parable patients in the placebo group (Gueorguieva et al.,
2011). Together with the demonstrated improvements in nat-
ural course groups, we could conclude that for some patients
with depression, “watchful waiting” could be the best clinical
option. Indication rules are urgently needed to deﬁne charac-
teristic patient features for these three treatment options (see
Table 1).
Table 1
Clinical decision making for treatments in depression and psychosis.
Received treatment
Best treatment Drug Placebo “Watchful
waiting”
Drug Adequately
treated
Treatment
potential not
used
Treatment
potential not
used
Placebo Negative
treatment
effects
predominate
Adequately
treated
Treatment
potential not
used
“Watchful waiting” Negative
treatment
effects
predominate
Negative
treatment
effects
predominate
Adequately
treated
Current knowledge on natural course, placebo and drug responses in psychosis andig. 2. Results of the study of Leuchter et al. (2014), conﬁrming that positive effects
n placebo groups are higher than those in a supportive care only group.
Treatment decisions depend on the expected beneﬁt–risk ratio,
ut risk assessment (in particular assessment of adverse events)
s notoriously unsatisfactory in clinical trials. Both in antidepres-
ant (Rief et al., 2009a) and in antipsychotic trials (Pope et al.,
010), about 80% of trials did not include adequate assessments
f side effects, making risk evaluation difﬁcult and delaying detec-
ion of drug-induced adverse events. For the clinician, it is hard
o decide whether the frequently reported symptoms during drug
reatments are genuine side effects of the drug or nocebo effects
Rief et al., 2009b). Besides more general symptoms, further critical
dverse events for antidepressants and antipsychotics are reduc-
ion of life expectancy in elderly mainly caused by falls or strokes
Brown et al., 2010; Sørensen et al., 2013), type II diabetes mellitus
Wu et al., 2014), reduction of brain volume in antipsychotics (Frost
t al., 2010; Ho et al., 2011), or damaging effects in the offspring if
he mother is taking antidepressants during pregnancy (Ansorge
t al., 2004; Ross et al., 2013; Weikum et al., 2012). Critical effects
f long-term treatment before adulthood that were observed in
nimals (e.g., increased risk of anxiety and depression; the selec-
ive serotonin reuptake inhibitors (SSRI) paradox; Homberg et al.,
010; Iniguez et al., 2014) are understudied in humans. The clin-
cal implications for risk-beneﬁt evaluation of these effects need
urther investigation (Bourke et al., 2014).
Taken together, despite the clear and positive evidence for the
se of antipsychotics and antidepressants that have informed cor-
esponding treatment guidelines, there are substantial reasons to
earch for ways to improve treatment effectiveness, and to reduce
egative effects or the absence of expected positive effects. A
eeper understanding of how genuine drug effects on the brain
nteract with those arising from placebo mechanisms and context
actors, promises to develop improved treatment regimes.
. Placebo response: clinical effects and neurophysiological
nderpinnings
Major psychological mechanisms contributing to placebo
esponses are expectations, learning mechanisms (e.g., pre-
xperiences with similar treatments), observational learning, and
spects of the therapeutic relationship (Enck et al., 2013; Rief
t al., 2011). Mediators and moderators of placebo responses in
sychiatry mainly based on clinical trials have been summarized
Rutherford and Roose, 2013; Weimer et al., 2015). The strong
mprovements in placebo groups contribute to a small placebo-
rug group difference. The incremental effect of antipsychotics over
lacebo corresponds to a pooled effect size of Cohen’s d/Hedges
 of .51 (Leucht et al., 2009), which is at the edge of small toavioral Reviews 60 (2016) 51–64 53
moderate effect sizes, while effect sizes above .80 are considered
high and clinically meaningful. Moreover, these small to moderate
estimates of the beneﬁcial effect do not acknowledge the problem
of “publication bias” (“ﬁle drawer problem”; see above). The dif-
ference of responder rates between antipsychotic versus placebo
treatment in psychosis is 18% (42% and 25% respectively; Leucht
et al., 2009), further conﬁrming that more powerful intervention
approaches are needed. For antidepressants, about 50–80% of the
positive drug effects are already reported for the placebo groups
(Kirsch and Sapirstein, 1998; Rief et al., 2009a), and some overviews
are even more skeptical (Spielmans and Kirsch, 2014).
The ﬁrst question is whether these effects are in fact not based
on placebo mechanisms, but result from factors like regression to
the mean, repeated measurements, general symptom ﬂuctuation,
etc. Ideally, an untreated control group is needed to juxtapose the
natural course of the disease and the placebo improvement in a
given trial. However, no-treatment control groups are rarely useddepression indicates that for many patients, drug treatment is the best option, while
for  some patients, placebo treatments or “watchful waiting” would be better options.
As  long as clear indication rules are missing, the beneﬁt-risk-ratio is undetermined,
and clinical decision making leads to wrong treatment allocations. Frequency/cell
sizes are subject to estimations.
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inimal intervention group (e.g., supportive care). Strong evidence
or better improvement in the placebo group than in a support-
ve care group stems from a recently published trial (Leuchter
t al., 2014). The authors reported that supportive care was signiﬁ-
antly less effective than both medication application and placebo
pplication along with supportive care (see Fig. 2). Therefore, the
eneﬁts in the placebo groups in antidepressant trials do not seem
o be mere results of statistical artifacts and natural course, but are
enuine results of placebo mechanisms. Thus, treatment recom-
endations should factor in positive effects in placebo groups and
ometimes even in natural course groups (see Box 1).
. Neurobiology of placebo responses in mental disorders
Considering the efﬁcacy of placebo effects, their associated neu-
obiological underpinnings should be further speciﬁed. To date, few
tudies have investigated the neurophysiology of placebo effects
elated to mental disorders, using experimental designs addressing
rucial mechanisms such as emotion regulation or anxiety.
Petrovic et al. (2005) were one of the ﬁrst groups investigat-
ng the neurophysiological effects of expectation manipulation
n emotional perception in healthy volunteers, and they com-
ared these processes with well-established processes on placebo
nalgesia. Using fMRI, they found a shared modulatory network
nvolving the rostral anterior cingulate cortex (ACC) and the lateral
rbitofrontal cortex during both placebo effects on emotion and
lacebo analgesia. These effects were correlated with the subjec-
ive placebo effect and were predicted by the amount of treatment
xpectation. A recent study corroborated the observation that anx-
olytic placebo responses in healthy subjects are associated with
ecreased activity in brain areas relevant for emotional processing,
uch as the amygdala and insula, and increased activity in areas
nvolved in decision making and reward, such as in the subgenual
CC (Zhang et al., 2011).
Furmark et al. (2008) studied the neural correlates of anx-
ety reduction resulting from sustained placebo treatment in
atients with social anxiety disorder. Brain activity was  assessed
uring a stressful public speaking task by means of positron emis-
ion tomography (PET) before and after an 8 week treatment
eriod. Placebo-induced reductions in anxiety were accompanied
y attenuated amygdala activity. Intriguingly, this study linked
hese behavioral and neural ﬁndings with serotonin-related gene
olymorphisms, since the reduction in stress-induced amygdala
ctivity was only observed in subjects who were homozygous for
he long allele of the serotonin transporter-linked polymorphic
egion (5-HTTLPR) or the G variant of the G-703T-polymorphism
n the tryptophan-hydroxylase-2 gene promoter (TPH2, the rate-
imiting enzyme in the synthesis of serotonin in the CNS). In
he same study, the TPH2 polymorphism signiﬁcantly predicted
lacebo responses, whereby homozygosity for the G allele was
ssociated with more pronounced improvement in anxiety symp-
oms. In patients with social anxiety, connectivity changes between
he amygdala and dorsolateral prefrontal cortex with rostral
CC were shown to be associated with the individual anxio-
ytic response to SSRI treatment and placebo. These observations
upport the notion that similar expectancy-related mechanisms
ontribute to improvements in emotion regulation following
lacebo treatments and anxiolytic drugs (Faria et al., 2014).
While general emotion regulation and anxiety play a role in
ost psychiatric conditions, the speciﬁc neurophysiological pro-
esses involved in placebo responses have been reported amongst
atients with depression. Leuchter and colleagues have used serial
uantitative electroencephalography (qEEG) in patients with major
epression enrolled in a 9 week double-blind placebo controlled
tudy in which the SSRI ﬂuoxetine or venlafaxine, a serotoninavioral Reviews 60 (2016) 51–64
and norepinephrine reuptake inhibitor (SSNRI), were the active
medication. Placebo responders showed a signiﬁcant increase
in prefrontal brain activity early in treatment which was not
observed in placebo non-responders or in patients responding or
not responding to the medication (Leuchter et al., 2002). An engage-
ment of prefrontal brain areas in placebo responses in depression
is substantiated by other brain imaging techniques. Changes in glu-
cose metabolism in depressive male patients were analyzed after
6 weeks treatment with the anti-depressant ﬂuoxetine or placebo
using PET (Mayberg et al., 2002). The placebo response was associ-
ated with metabolic increases in the prefrontal cortex, but also in
the ACC, pre-motor, parietal and posterior cingulate cortex, while
decreased activity was observed in the subgenual cingulate cor-
tex, parahippocampus, and thalamus. These results were extended
by a PET study investigating depressive patients after receiving
placebo pills, with half of the patients being informed that this
would be an active antidepressant (Pecin˜a et al., 2015). This later
group reported signiﬁcant decreases in depression scores. These
reductions were associated with increased -opioid neurotrans-
mission in a network of regions implicated in emotion regulation,
namely the subgenual ACC, nucleus accumbens, midline thalamus,
and amygdala.
As has been shown for placebo responses in anxiety disorders,
genetic variability also contributes to inter-individual differences
in placebo responses in depression. Leuchter, for instance, showed
that genetic polymorphisms modulating monoaminergic tone
(polymorphisms in genes encoding the catabolic enzymes catechol-
O-methyltransferase and monoaminooxidase) are related to degree
of improvement during placebo treatment of subjects with major
depressive disorder (Leuchter et al., 2009).
Although most research of the neurobiological underpinnings of
placebo responses in depression is still in an early stage, the avail-
able evidence supports the notion that neurobiological trajectories
for placebo responses in mental disorders involve expectation,
emotion and reward-related circuitry (Benedetti et al., 2005;
Murray and Stoessl, 2013; Wernicke and Ossanna, 2010). The lat-
ter nicely ﬁts in with the observations that increased subjective
reward experience affects treatment efﬁcacy with anti-depressive
medication (Wichers et al., 2009). Furthermore, inter-individual
variability in the placebo response in anxiety and depression seems
to be, at least in part, determined by variability in genes related
to monoaminergic tone, particularly serotonin. Future studies will
hopefully unravel the neurobiological underpinnings of placebo
responses in anxiety and depression and, importantly, their con-
tribution to or interaction with active antidepressant treatments
in more detail.
Very little is known about the neurobiology of placebo responses
in schizophrenia. Considering the role of dopamine in psychosis,
it is relevant that dopamine release is affected by expectation
effects and can be triggered by placebo applications (de la Fuente-
Fernandez et al., 2001; Schmidt et al., 2014). This is associated with
enhanced reward learning and modulations of learning-related sig-
nals in the striatum and ventromedial prefrontal cortex (Schmidt
et al., 2014). Expectations can also alter dopamine in patients
with schizophrenia who received placebo pills. These patients had
reduced BOLD activation in the ventral striatum, frontal cortex and
cingulate cortex in anticipation of loss, an effect that was  associated
with dopamine depletion. The ﬁndings of reduced dopamine-
related brain activity during -methylparatyrosine (AMPT) were
veriﬁed by reduced levels of dopamine in urine, homovanil-
lic acid in plasma and increased prolactin levels (Alves et al.,
2013). However, despite the conﬁrmation of effects of expec-
tation on dopamine release, in particular under anticipation of
losses, it remains unclear whether this affects the same neural
circuitries as in psychosis. Finally, Honey et al. (2008) used a
ketamine model for psychosis. The brain responses to cognitive
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ask demands under placebo predicted the expression of psy-
hotic phenomena after drug administration. Fronto-thalamic
esponses to a working memory task were predictors of the ten-
ency of subjects to develop more negative symptoms under
etamine.
More speciﬁc evidence for the interaction of placebo mech-
nisms such as expectation and neurophysiological processes in
chizophrenia is lacking. While initial links between expectation,
earning and dopamine release have been established, their func-
ional relevance and overlap with psychosis-relevant circuitries
eeds further investigation.
. Excursion: why neuroplasticity processes are crucial for
uccessfully treating mental disorders: a brief overview
In the following sections, we will introduce basic concepts and
ndings of neuroplasticity in humans, their relevance in depression
nd schizophrenia, and we will present some illustrative examples
f their relevance from animal research. Afterwards (Sections 5–7),
e will present speciﬁc and more detailed results on neuroplas-
icity after antidepressant and antipsychotic treatments in animal
esearch, as well as the interaction of these effects with individual
nd environmental inﬂuences.
.1. Neurogenesis as basis of human adaptation processes
Neural plasticity describes the process of continuous anatom-
cal and physiological restructuring of the brain, governed by a
ifelong developmental trajectory, and substantially modulated by
epi-)genetic, neurochemical, endocrine, inﬂammatory, social, and
ther environmental stimuli. Neuroplasticity offers the basis for the
apacity to adapt permanently to a changing physical and inter-
ersonal environment; therefore adequate neuroplastic processes
re a precondition for mental health, and successful drug treat-
ents must be reﬂected under the perspective of neural plasticity.
he conceptualization of human brain functions has changed dra-
atically after realizing that neurons are in a continuous process
f dendritic branching, elongation, and pruning, which is substan-
ially stimulated by brain × environment interactions (Zatorre et al.,
012). Learning and memory trainings can cause such neuroplas-
ic changes (Takeuchi et al., 2013). Such neuroplasticity seems to
ollow a two-stage process: on a short-term perspective, rapid and
ransient changes of the functioning of neural pathways occur,
hich are followed on a long-term perspective by more prolonged
hanges in the structural organization of neural pathways. Neuro-
lasticity can contribute to the maintenance of mental disorders
e.g., through continuously distorted information processing), but
lso to overcoming them (Morris et al., 2014).
A key human adaptation process is contextual learning, i.e.,
elating important events to a speciﬁc spatial, temporal, intero-
eptive, cognitive or interpersonal context (Maren et al., 2013).
herefore contextual learning can also play a role in the develop-
ent of placebo reactions, e.g., by linking a speciﬁc environment
ith the expectation of successful treatments. On a neuroana-
omical level, a network of structures including hippocampus,
refrontal cortex and amygdala is involved in contextual learn-
ng. On a cellular level, adaptation requires plasticity as shown
y a wealth of animal research. An important phenomenon of
europlasticity enabling contextual learning is adult neurogene-
is, especially in the hippocampal formation. Neuronal progenitor
ells are generated in the subventricular zone and in the dentate
yrus of the hippocampal formation and provide a continuous sup-
ly of new neuronal elements (Fuchs and Flugge, 2014). Inhibition
f neurogenesis in the hippocampus disrupts contextual learning
Hernandez-Rabaza et al., 2009). The role of adult neurogenesis isavioral Reviews 60 (2016) 51–64 55
not limited to general contextual learning, but it also plays a role
in processes such as fear conditioning, recognition, spatial mem-
ory, pattern separation, exploratory behavior, behavioral inhibition
in dangerous situations, anxious behavior, and regulation of the
hypothalamic–pituitary–adrenal axis (Cameron and Glover, 2015).
Positive modulators of neurogenesis are environmental stimuli,
exercise, estrogens, and growth factors like vascular endothe-
lial growth factor (VEGF) or brain-derived growth factor (BDNF).
Intriguingly, antidepressants have also been shown to modulate
neurogenesis (see below). Negative modulators are aging, acute
and chronic stress, glutamatergic (NMDA) receptors, and glucocor-
ticoids. Plasticity that is based on neurogenesis introduces a speciﬁc
time frame, that is, effects are to be expected within weeks but not
days.
5.2. Neuroplasticity in patients with depression and during
antidepressant treatments
The neurogenesis hypothesis of mental disorders postulates
that (a) a decrease in neurogenesis may  contribute to the onset
or maintenance of mental disorders like depression and anxiety
and (b) antidepressant agents require adult neurogenesis in the
hippocampus for their effects. These neuroplastic processes can be
further inﬂuenced by individual factors and environmental pro-
cesses. Mental disorders are not only characterized by emotional
changes, but also by speciﬁc deﬁcits in cognition, i.e., attention and
memory processes, and expectations (e.g., focus of attention on
negative events in depression (Rief et al., 2015). Depression-speciﬁc
attention and memory processes lead to neuroplastic changes that
can further stabilize the depressive state and lead to depression
persistence (Armstrong and Olatunji, 2012; Peckham et al., 2010;
Sumner et al., 2010). On the other hand, some of the observed
neuroanatomical abnormalities of depressed patients can also rep-
resent a precondition or risk factor for symptom development
(Goodkind et al., 2015). Patients with major depressive disorders
have low hippocampal volumes compared to healthy comparison
subjects (Zou et al., 2010), and there is electrophysiological evi-
dence that neuroplasticity is decreased in patients with depression
compared to healthy controls (Player et al., 2013).
All classes of antidepressants seem to modulate adult neuro-
genesis as shown in animal studies. These include SSRIs, tricyclic
substances, MAO-inhibitors, electroconvulsive treatment (Malberg
et al., 2000), SSNRIs (Asokan et al., 2014), and the 5-HT2c antag-
onist agomelatine (Banasr et al., 2006). Antidepressants increase
neurogenesis in the subgranular zone of the dentate gyrus (Becker
et al., 2008; Czeh et al., 2006; Malberg et al., 2000), and neu-
rogenesis appears to be essential for their therapeutic efﬁcacy
(Santarelli et al., 2003). Also, increased neurogenesis paralleled
reduced depression-like behavior after antidepressant treatment
(Becker et al., 2008; Czeh et al., 2006; Santarelli et al., 2003).
As a general model we postulate that antidepressants promote
hippocampal plasticity, but that an enriched environment, new
experiences and skills training are required to repair maladaptive
network function and to foster new adaptive ones. This view of the
crucial role of neurogenesis and neuroplastic process during drug
treatments and their interaction with environmental inﬂuences is
supported by detailed and speciﬁc evidence summarized in reviews
of animal research, which will be provided in a later section.
5.3. Neuroplasticity in patients with schizophrenia and during
antipsychotics treatmentsSchizophrenia may  be conceptualized as a neurodevelopmental
disorder, related to genetic and environmental risk factors that
interfere with the structural and functional reorganization of
neural networks (Meyer-Lindenberg and Tost, 2012, 2014). A
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rogressive reduction in gray matter volume has been observed
n longitudinal trials, especially in the bilateral anterior insula
nd dorsal ACC, but also variations of dorsal ACC and insula vol-
me  are reported in psychosis (Goodkind et al., 2015). These
euroimaging observations are thought to reﬂect an enduring dis-
urbance of experience-dependent synaptic plasticity, including
lso dorsolateral prefrontal cortex and hippocampal formation
Meyer-Lindenberg and Tost, 2014). The neural disorganiza-
ion in long range connectivity circuits seems to be related to
llness-typical psychological symptoms, such as cognitive deﬁcits,
elusions, and negative symptoms. Finally, the brain is in a state
f not reacting to illness-incongruent environmental information
e.g., neglect of a helpful neighbor’s behavior in the case of para-
oid delusion), but carries forward the delusional interpretation
f events, again leading to states of anxiety and mistrust that
re associated with corresponding neural plasticity processes. The
stablishment of a vicious circle of sensitized neural networks
aintaining symptoms, and misinterpretation of environmental
timuli supporting these disorder-speciﬁc neural plasticity pro-
esses can be postulated.
The contribution of antipsychotic treatments to neuroplas-
ic processes became a critical point of discussion after the
ublication of challenging results indicating that there is a relation
etween negative brain developments and lifetime drug expo-
ure to antipsychotics (Fusar-Poli et al., 2013; Ho et al., 2011). In
ontrast, second generation drugs like olanzapine and risperidone
eem to be related to increased neurogenesis in the hippocampus
nd supraventricular zone (Wakade et al., 2002), and in prefrontal
ortex and striatum (Wang et al., 2004), compared with haloperidol.
ecent evidence indicates that short-term treatment with antipsy-
hotics modulates the connectivity between brain areas differently
Sarpal et al., 2015). Animal research can help to better understand
he neurobiological processes during drug treatments, as well as
heir interaction with environmental inﬂuences on neural plastic-
ty. Therefore, these results will be highlighted in the following
ections.
. Neuroplasticity and antidepressant drug treatments:
nimal research
Animal models allow more detailed analyses of neurobiological
rocesses, and better control of environmental inﬂuences com-
ared to studies with humans. However, their generalizability to
linical applications in humans is rendered difﬁcult given differ-
nces in dosage, application form and duration of treatments,
imited validity of the “clinical models” for mental disorders in
nimals, and the fact that “healthy” subjects are often used in ani-
al  drug studies aiming at inferring brain reactions in mentally ill
atients.
New treatment concepts postulate that the recovery from
epression in response to antidepressant treatment is reﬂected in
nd due to structural and functional changes in neuronal networks
mplicated in emotion regulation (Castrén, 2005; Duman and
ghajanian, 2012; Krishnan and Nestler, 2010). These processes
ave been investigated in animal models of depression, such as
earned helplessness, social defeat and inescapable stress. In rats,
hese states are associated with reduced adult neurogenesis (Ho
nd Wang, 2010; Lehmann et al., 2013; Malberg and Duman, 2003).
ice, in which neurogenesis is disrupted using irradiation, no
onger respond behaviorally to antidepressants. This was shown by
antarelli et al. (2003), who demonstrated that the increase in adult
eurogenesis in the dentate gyrus induced by SSRIs is required for
heir effectiveness in reversing depression-related behavior, and
hat serotonin auto-receptors are strongly involved in modulat-
ng relevant drug-induced neurotrophic and behavioral effects. Aavioral Reviews 60 (2016) 51–64
related ﬁnding suggests that SSRIs lead to a dematuration of mature
granule cells in the dentate gyrus, as indicated by a strongly reduced
expression of the mature cell marker calbindin (Kobayashi et al.,
2010). SSRIs might thus induce a plastic state of the brain that is
typically seen in younger organisms (Castrén, 2013). While this
result mainly relates to hippocampal structures, antidepressants
apparently exert part of their action independent of hippocampal
structures (Petrik et al., 2012); however, the effects of antidepres-
sants on neuroplasticity in other areas is less clear (Dringenberg
et al., 2014).
Since the seminal work of Hubel and Wiesel (Hubel et al., 1977)
the visual system is a well-established model to study environ-
mental effects on neuronal development and plasticity (Hensch,
2005). By means of this system, (Vetencourt et al., 2008) showed
that closing one eye in adult rats treated with the antidepressant
SSRI ﬂuoxetine led to a strong shift in the responsiveness of visual
cortical neurons in favor of the open eye. The observed shift in
responsiveness in adult rats was  paralleled by increased expres-
sion of the neurotrophic factor BDNF, and similar changes were
observed in infant rats during the early postnatal critical period,
indicating that ﬂuoxetine treatment initiated a process of neuronal
plasticity typically not seen in adult controls. Importantly, neuronal
plasticity following ﬂuoxetine even allowed functional recovery of
a miswired neuronal network in adult rats in which one eye had
been closed during early development. However, recovery was only
seen when drug treatment and appropriate rehabilitation, in this
case patching the better eye, was combined. An effect of antidepres-
sants on neuronal plasticity markers in the visual system has also
been reported in humans (Normann et al., 2007). Finally, plasticity
induced by antidepressants, electroconvulsive therapy, exercise or
environmental enrichment may  also include dendritic arborization,
synaptogenesis and synaptic strength (Castrén, 2013).
7. Neuroplasticity and antipsychotic drug treatments:
animal research
The animal literature on the neurobiological effects of antipsy-
chotics is controversial because several studies have reported
neurotoxic effects whereas others have yielded positive neuro-
plastic results. Part of this ambivalence may  be due to the choice
of assays (e.g., cell cultures), drugs, and their doses. Neurotoxic
effects can include mechanisms such as apoptosis, mitochondrial
deﬁcits, excessive glutamate activation, or DNA fragmentation.
These effects are more likely in case of, but not exclusive for
haloperidol compared to atypical antipsychotics. They are often
discussed in the context of neurological side effects, especially tar-
dive dyskinesia (for review see Dean, 2006).
In schizophrenia, special interest was  given to neuroplastic pro-
cesses of the (neo-) striatum, and increased striatal volumes have
been reported with haloperidol (Chakos et al., 1998). This effect was
most pronounced in case of animals developing vacuous chewing
movement, an animal equivalent for drug-induced extrapyramidal
symptoms which are attributed to blockade of striatal dopamine
D2-receptors and its consequences. The increase of striatal volume
was found in case of persistent treatment with haloperidol and
clozapine, but not risperidone, and decreased volumes were found
with olanzapine (Andersson et al., 2002). Striatal volume increases
were reversible by several weeks of drug withdrawal (Vernon et al.,
2012).
In the neocortex (frontal and parietal), volume reductions after
chronic antipsychotic treatments (haloperidol, olanzapine) pre-
vails (Frost et al., 2010). These volume reductions were not due
to loss of neurons or glia, since their densities per volume were
actually increased, suggesting that the absolute tissue losses may
be due to decreases in axons, myelinisation, dendritic spines, or
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lood capillaries. Again, the cortical volume decreases after chronic
aloperidol were reversible after several weeks of drug with-
rawal (Vernon et al., 2012). Finally, results for the hippocampus
re equivocal, including volume increases (haloperidol) (Schmitt
t al., 2004), decreases (olanzapine) (Barr et al., 2013), or no
hanges (haloperidol, clozapine, and olanzapine) (Vernon et al.,
011).
Together, available evidence supports the notion that the neos-
riatum increases its size with chronic haloperidol and olanzapine
reatments, whereas parts of the neocortex seem to decrease in
olume. Hippocampal ﬁndings are equivocal so far, possibly due to
ifferences in drug treatments and/or anatomical criteria to ana-
yze this rather heterogeneous structure. Initial results indicate
hat antipsychotics like haloperidol might reduce the connectivity
etween several brain regions, including prefrontal cortex, hip-
ocampus, and pallidum (Gass et al., 2013), which can further
ontribute to modulations of brain plasticity.
On a cellular level, antipsychotic treatments (usually chronic
aloperidol or chlorpromazine) can lead to increases in axon ter-
inal sizes, postsynaptic densities, and numbers and types of
ynapses (striatum), and to decreases in dendritic spine density
nd asymmetric synapses (Benes et al., 1985; Kerns et al., 1992;
ranova et al., 1991). These effects may  be speciﬁc for longer
asting drug treatments or ﬁrst-generation antipsychotics (Frost
t al., 2010; Klinzova et al., 1990).
The effects of antipsychotics on neurotrophins have been
xtensively investigated, largely driven by the hypothesis that
chizophrenia may  be due to early malfunction of neurotrophic
actors, resulting in structural disorganisation locally in the brain
Angelucci et al., 2005). Some atypical antipsychotics can increase
DNF and nerve growth factor (NGF) activity in the striatum,
ippocampus, and neocortex, whereas haloperidol seems only
o promote NGF activity (Horacek et al., 2006). These plasticity-
elevant effects can explain the “delayed onset of the antipsychotic
ffect”, suggesting that re-modelling of neuronal structures and cir-
uits is required for this effect (Horacek et al., 2006). More recently,
uvenile treatment with the atypical antipsychotic lusaridone was
hown to be effective in preventing stress-induced losses of BDNF
n a rat model (Luoni et al., 2014). To summarize, the effects of
ntipsychotics on remodeling of brain structures can be driven via
eurotrophin pathways.
Another link between antipsychotic drugs and neuroplasticity
s long-term potentiation (LTP). Various antipsychotics with D2
ntagonistic properties have different effects on LTP in laboratory
nimals and humans (Price et al., 2014). The authors concluded in
heir summary that acute antipsychotics rather consistently impair
TP, both in case of classical and atypical antipsychotics (except for
lozapine and olanzapine).
Enhanced cell proliferation is usually not observed in case of
aloperidol (prefrontal cortex, neostriatum, subventricular zone,
nd dentate gyrus) (Halim et al., 2004; Schmitt et al., 2004; Wakade
t al., 2002; Wang et al., 2004), in contrast to chronic regimens with
he atypical antipsychotics olanzapine, risperidone, clozapine, and
uetiapine (Green et al., 2006; Halim et al., 2004; Kodamo et al.,
004; Luo et al., 2005; Wakade et al., 2002; Wang et al., 2004).
owever, in some studies, where the types of newly formed cells
ere identiﬁed, no evidence of true neurogenesis was  obtained
Kodamo et al., 2004; Wang et al., 2004), and it was assumed that
nhanced cell proliferation was due to endothelial cells and oligo-
endrocytes. Kodamo et al. (2004) showed actual neurogenesis in
he dentate gyrus with chronic olanzapine, an effect which was
omparable to that of chronic ﬂuoxetine treatment. Also, Luo et al.
2005) showed that chronic quetiapine was able to reverse a stress-
nduced decrease of cell proliferation in the SGZ, and of BDNF levels
n the hippocampus. Finally, several ﬁndings indicate that the atyp-
cal antipsychotics have no effect on cell survival, that is, theiravioral Reviews 60 (2016) 51–64 57
outcomes were mainly due to effects on cell formation (Green et al.,
2006; Halim et al., 2004; Wang et al., 2004).
8. Interactions of psychopharmacological actions and
environmental inﬂuences: Animal research
Despite the problems of generalizing animal research to
humans, animal studies allow much better control of contextual
factors and therefore offer unique insights into the neuroplasticity
processes induced by the interaction of drug intake with behavioral
and contextual factors of the treatment environment, which will be
reviewed in the following.
8.1. Antidepressants
Environmentally triggered experiences can inﬂuence the
amount and direction of neural plasticity changes. Neuroplastic
effects that are similar to those induced by antidepressants have
been reported for environmental enrichment (Hendriksen et al.,
2010), physical skills training (Curlik et al., 2013), and exercise (Yau
et al., 2014). The social context is also of relevance for neuroplas-
ticity, which is conﬁrmed by the ﬁnding that successful coping
with social stress in monkeys is associated with increased hip-
pocampal neurogenesis (Lyons et al., 2010). The crucial question is
how these neuroplastic effects triggered by non-pharmacological
aspects interact with the neurobiological effects of the drug.
According to the network hypothesis (Castrén, 2013), enhanced
neuronal plasticity following antidepressant treatment renders the
organism more susceptible to environmental inﬂuences, and thus
allows the organism to better adapt to alterations in environmen-
tal conditions, eventually leading to recovery. This hypothesis is
consistent with the delayed emergence of the clinical effects of
antidepressants because recovery is not observed as the result from
an immediate increase or decrease in a single neurotransmitter
level; rather the early neurochemical effects of antidepressants
initiate a process of neuronal plasticity through which emotion-
regulating brain structures better represent current environmental
inﬂuences. Environmental factors are thus proposed to interact
with drug effects, leading to environment-speciﬁc consequences
for brain modiﬁcations during identical drug treatments.
In order to further investigate the association of neuronal plas-
ticity induced by antidepressants with appropriate environmental
stimulation in the context of emotion regulation, Karpova et al.
(2011) performed a series of experiments on fear extinction in adult
mice. They ﬁrst exposed mice to a standard fear learning paradigm,
in which mice learned to associate a previously neutral tone with
foot shock application by using a conditioning procedure, as indi-
cated by an increase in freezing behavior in response to the tone
in absence of the shock. Then, mice were repeatedly confronted to
the tone alone during extinction trials, similar to exposure therapy
for phobias in humans. The authors showed that extinction train-
ing led to a reduction in freezing behavior, yet the beneﬁcial effects
were short-lasting and spontaneous recovery of the fear response
as well as fear renewal were detectable. However, when ﬂuoxe-
tine was  administered during extinction training, this combination
resulted in a long-lasting reduction in the fear response, with no
signs of spontaneous recovery and fear renewal, similar to fear
extinction studies in young mice (Gogolla et al., 2009). The positive
effect of ﬂuoxetine was due to an enhanced efﬁcacy of extinction
training under ﬂuoxetine, since ﬂuoxetine alone did not alter freez-
ing behavior. This suggests a synergetic effect of exposure therapy
and ﬂuoxetine treatment.
Consistently with the network hypothesis, ﬂuoxetine was found
to induce a plastic state in the basolateral amygdala (Karpova
et al., 2011), a key brain structure for fear learning (LeDoux, 2000).
5 iobeh
S
n
e
d
(
c
l
i
t
t
w
t
r
i
t
O
r
(
t
p
(
w
R
i
(
n
d
o
(
f
(
p
a
m
f
ﬂ
c
p
p
f
a
l
t
i
a
W
t
d
m
s
s
h
j
t
s
c
a
t
c
a
p
h
a8 W.  Rief et al. / Neuroscience and B
peciﬁcally, ﬂuoxetine was  shown to enhance the levels of the
eurotrophic factor BDNF while reducing the number of neurons
xpressing the calcium buffer parvalbumin in the basolateral amyg-
ala. Importantly, both BDNF (Peters et al., 2010) and parvalbumin
Wöhr et al., 2015) modulate the organism’s ability to adapt to
hanges in the environment as assessed by extinction and reversal
earning paradigms. For instance, Peters et al. (2010) showed that
nfusion of BDNF into the prefrontal cortex accelerates fear extinc-
ion in rats. Consistently, in BDNF heterozygous mice ﬂuoxetine
reatment was less efﬁcient and spontaneous recovery of fear as
ell as fear renewal were detectable, while BDNF overexpression in
he basolateral amygdala led to a long-lasting reduction in the fear
esponse (Karpova et al., 2011). Together, these ﬁndings strongly
ndicate that SSRI treatments render the organism more susceptible
o environmental changes through enhanced neuronal plasticity.
f note, evidence for stronger effects of combined therapies was
ecently also obtained in humans (Schneier et al., 2012).
Subsequent studies conﬁrmed the ﬁndings obtained by
Karpova et al., 2011). The combination of ﬂuoxetine and extinc-
ion training resulted in a unique change in expression of synaptic
roteins involved in excitatory and inhibitory neurotransmission
Popova et al., 2014) consistent with the action of d-cycloserine,
hich is also known to enhance fear extinction (Walker et al., 2002).
emarkably, ﬂuoxetine was even found to promote fear extinction
n a mouse strain characterized by strongly impaired fear extinction
Camp et al., 2012). Moreover, it has been shown that ﬂuoxetine sig-
iﬁcantly reduces fear reinstatement even after discontinuation of
rug treatment (Deschaux et al., 2011) and that post-extinction ﬂu-
xetine prevents stress-induced reemergence of extinguished fear
Deschaux et al., 2013). In contrast to ﬂuoxetine, this extinction-
acilitating effects was not seen with nortriptyline or mirtazapine
Melo et al., 2012).
The ways in which environmental conditions interact with the
harmacological action of antidepressants was further assessed in
 recent study (Dankoski et al., 2014). In this study, the authors
easured electrically evoked serotonin release by means of in vivo
ast scan cyclic voltammetry and compared release rate, net over-
ow, and clearance in single- and group-housed mice exposed to
hronic treatment of citalopram, another SSRI. While chronic citalo-
ram treatment in group-housed mice facilitated serotonin release
robably due to serotonin auto-receptor desensitization, no such
acilitation was seen in mice exposed to social isolation. Clear-
nce was not affected by drug administration. Importantly, the
ack of facilitated serotonin release following chronic citalopram
reatment in single-housed mice was paralleled by a lack of drug-
nduced changes in the marble burying test, a test typically used to
ssess anxiety-like and repetitive behavior (Thomas et al., 2009).
hile in group-housed mice, citalopram had an anxiolytic effect,
he behavior of mice exposed to single-housing was not altered by
rug treatment. In the open ﬁeld test, however, citalopram treat-
ent resulted in a more anxious phenotype. Consistently, the SSRI
ertraline clearly reduces depression-related behavior in the forced
wim test in rats exposed to environmental enrichment or standard
ousing, but less in rats that were single-housed for six weeks as
uveniles after weaning from the mother (Yildirim et al., 2012). Ini-
ial evidence for this association has been found in human studies
uggesting that stress, e.g., absence of social support networks, can
ontribute to treatment-resistant depression and anxiety (Karelina
nd DeVries, 2011). These ﬁndings show that plasticity in the sero-
onergic system is responsive to environmental stressors, which
an determine the effect of pharmacotherapies using SSRIs.
All these animal studies indicate that the beneﬁcial effects
ssociated with changes in neuronal plasticity induced by antide-
ressants depend on appropriate environmental stimulation. This
as important neuroscientiﬁc and clinical implications. Firstly, vari-
ble and incomplete efﬁcacy of antidepressants might be explainedavioral Reviews 60 (2016) 51–64
by the so far mostly neglected interplay between drug treatment
and environmental factors. Secondly, a deeper understanding of
this interplay offers the potential to improve pharmacotherapy
through behavioral interventions. Finally, the network hypothesis
predicts that antidepressant treatment under adverse environmen-
tal conditions might promote “maladaptive plasticity”, resulting in
a further deterioration rather than improvement in clinical symp-
toms (Castrén, 2013). This implies that antidepressant therapy
would be strictly discouraged if life circumstances are expected to
be negative. In fact, this is exactly what was shown by a pioneering
study (Branchi et al., 2013). The authors treated adult mice with
chronic ﬂuoxetine while exposing them either to a stressful envi-
ronment or to an enriched environment after exposure to a chronic
stress period for inducing a depression-related behavioral pheno-
type. If increased serotonin levels elevate mood per se, ﬂuoxetine
is expected to reduce the depression-related behavioral pheno-
type in mice irrespective of environmental conditions. However,
if ﬂuoxetine leads to increased neuronal plasticity rendering the
organism more susceptible to the inﬂuences of the environment,
SSRIs applied during a stressful environment might lead to more,
but not less depression-related behavior, whereas SSRIs applied
during enrichment would again be expected to reduce depression-
related behavior. The authors found that saccharin preference, an
animal paradigm for assessing depression-like anhedonia, showed
oppositional results depending on environmental condition: in
mice treated with chronic ﬂuoxetine in an enriched environment,
anhedonia was reduced, while the depression-related behavioral
phenotype was  even more prominent if ﬂuoxetine was adminis-
tered in a stressful environment. The worsening of the behavioral
phenotype of depression was  paralleled by lower levels of the neu-
rotrophic factor BDNF and increased corticosterone levels. These
ﬁndings strongly suggest that the effects of SSRIs are driven by
the environment and that “unfavourable” environmental factors
can impair or even reverse the intended treatment outcome in
antidepressants. “Unfavorable” and adverse environmental condi-
tions might be considered contraindications for pharmacotherapies
using SSRIs, such as “impoverished treatment environments” (e.g.,
in socially disadvantaged conditions; Meyer-Lindenberg and Tost,
2012), which are inherently associated with the majority of psy-
chiatric disorders. It is therefore especially important to investigate
ways to overcome the negative impact of social isolation on out-
comes in mental disorders.
8.2. Antipsychotics
The crucial inﬂuence of treatment context and behavior on
drug response has also been investigated for antipsychotics. Strong
effects on neural processing after drug intake have been shown to
be caused by physical activity. This is relevant in the context of cell
proliferation and neurogenesis, since physical exercise has repeat-
edly been shown to enhance these processes in rodents, and these
effects are probably due to upregulation in neurotrophic factors,
such as BDNF (for review see Zoladz and Pilc, 2010). The stud-
ies available so far (Alegre Baptista et al., 2013; Teixeira et al.,
2011) show that treadmill exercise or swimming for several weeks
can reduce or prevent extrapyramidal symptoms (like catalepsy or
vacuous chewing movements) induced by chronic treatment with
haloperidol, and that running wheel exercise partly prevented hip-
pocampal volume loss (mainly dentate gyrus and CA1) induced by
chronic treatment with olanzapine (Barr et al., 2013). Swimming
exercise prevented drug-induced lipid-peroxidation cortically and
subcortically (Czeh et al., 2006; Teixeira et al., 2011). The authors
of these studies assumed that cardio-metabolic factors (linked to
glucose and fat) in case of olanzapine may play a role, for exam-
ple that olanzapine via enhanced glucose availability may  lead to
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oxic effects in the hippocampus, which are prevented by exercise-
nhanced energy consumption.
Another way of showing the interaction between drug effects
nd environment effects is the investigation whether drug effects
re prone to learning processes. Such an effect would imply
hat based on Pavlovian conditioning, environmental stimuli have
igniﬁcant impact on drug effects, in particular after long-term
reatments. These inﬂuences have been shown especially in the
ontext of human placebo mechanism studies (Doering and Rief,
012). In animals, associative and contextual factors have repeat-
dly been investigated in case of haloperidol. Catalepsy can be
ssessed in animals as a behavioral correlate of drug action, which
s also relevant for the extrapyramidal side effects of antipsy-
hotics. In rats and mice, haloperidol leads to a dose-dependent
ffect on catalepsy, since low doses usually induce no or only
oderate acute effects, whereas pronounced catalepsy is typi-
al in case of higher doses. However, repeated higher doses can
ead to tolerance, whereas sensitization (i.e., enhanced catalepsy)
s more typical for low doses. These phenomena can be manip-
lated via conditioning: cataleptic tolerance to a challenge dose
1.5 mg/kg) occurred in a previously drug-paired environment but
ot in a distinct saline-paired environment (Jonas et al., 2013).
he authors argued “that cues previously associated with neuroleptic
dministration are critical for engaging mechanisms that counteract
he cataleptic effect of haloperidol in producing tolerance”, that is, such
olerance may  be due to classical conditioning (Hinson and Siegel,
982). Thus, environmental cues paired with drug administration
ay  become conditioned stimuli, which can elicit compensatory
esponses, thereby reducing drug effectiveness.
The sensitization effect in low doses (Klein and Schmidt, 2003)
f haloperidol (0.25 mg/kg) is also subject to conditioning. The ﬁrst
ow-dose exposure induced no or only low levels of catalepsy, but
ed to increased catalepsy with repeated injections. When subse-
uently challenged with saline (i.e., placebo), substantial levels of
atalepsy were observed, arguing for conditioning of this effect (see
lso (Banasikowski and Beninger, 2012; de Sousa Moreira et al.,
982). This context-dependency of sensitization in haloperidol-
nduced catalepsy was independent of the novelty of the test
ontext, since it was observed in novel as well as familiar envi-
onments (Wiecki et al., 2009). Also, the sensitized response was
radually extinguished by repeated saline experiences in the acqui-
ition context and showed partial renewal after a subsequent
aloperidol challenge (Amtage and Schmidt, 2003). It was sug-
ested that catalepsy sensitization may  reﬂect a kind of enhanced
triatal “NoGo” learning, which suppresses action execution by dis-
nhibiting D2-dependent striatopallidal projections (Wiecki et al.,
009). This ﬁnding can be linked to the fact that chronic haloperidol
an promote corticostriatal LTP in animals and humans (Centonze
t al., 2004; Waltz et al., 2007). Also, catalepsy sensitization
eems to have memory-like properties, since its consolidation is
mpaired by post-trial administration of a glutamatergic antagonist
Riedinger et al., 2011).
More recently, the effect of environmental cues on antipsy-
hotic outcomes was investigated, using hyperlocomotion to the
sychotomimetic phencyclidine as antipsychotic index (Sun et al.,
014). The authors found that “more exposures to the test envi-
onment under the inﬂuence of haloperidol (but not clozapine or
lanzapine) caused a stronger inhibition than fewer exposures,
ndicating a strong environmental modulation” (see also Zhang and
i, 2012). Finally, maladaptive environments (rearing rats, which
re highly social animals, in isolation) affects the prefrontal neu-
ochemical responsiveness to atypical antipsychotics (olanzapine,
lozapine), but not to haloperidol (Heidbreder et al., 2001).
To summarize, in animal models there is clear evidence that
nvironmental inﬂuences steer the effects of antidepressant and
ntipsychotic drugs even on a very basic neurobiological level.avioral Reviews 60 (2016) 51–64 59
Maladaptive environmental inﬂuences or sedentary behavior can
lead to detrimental effects of these drugs on a clinical outcome level,
and they can increase the risk of adverse side effects, while sup-
portive environmental inﬂuences can ensure the expected positive
effects of psychopharmacological interventions (Fig. 3).
9. Implications for treatment regimens
The summarized evidence strongly supports the notion that
drug action, placebo mechanisms, and contextual factors such as
environmental stimulation contribute to the therapeutic process in
mental disorders, and neuroplasticity offers a common platform to
understand where and how these processes interact. While many
treatment approaches lack a systematic combination of these prin-
ciples, drug treatments in psychiatry can only develop their full
potential if the pharmacological action is supported and steered by
environmental and behaviorally-triggered stimulation. First, drug
treatment should only be initiated if a positive beneﬁt-risk ratio
can be expected under the known environmental conditions (see
Box 1). If this cannot be expected, the next question is whether
verbal interventions of the psychiatrist/therapist can help to cre-
ate the environmental conditions necessary for treatment success
(Fig. 4).
Research on placebo mechanisms indicates that the start of
psychopharmacotherapy should be accompanied by optimizing
patient’s treatment expectations, addressing past treatment expe-
riences, and establishing a positive therapeutic interaction. During
the course of treatment, new learning situations challenging
depression-speciﬁc or psychosis-speciﬁc beliefs, social interaction
experiences, and environmental input should be established that
support overcoming the mental disorder. Some of these behavioral
and contextual factors can be considered to be more general factors
(such as physical activity and social contacts). From a psycholog-
ical point of view, conceptualizations of mental disorders focus
on disorder-speciﬁc expectations (Rief et al., 2015), and treatment
contexts should be created that maximally violate these negative
disorder-speciﬁc expectations.
Expectations are predictions about future events that are asso-
ciated with the activation of neural networks, and this process
can facilitate the disorder-speciﬁc perception and interpretation
of events (e.g., expectation of pain activates pain-relevant brain
structures including the corresponding somatosensory ﬁelds;
Summerﬁeld and de Lange, 2014). Therefore disorder-speciﬁc
expectations can be postulated to be crucial factors contribut-
ing to the maintenance of mental disorders. Depressed patients
expect negative consequences from their behavior, negative feed-
back from others, and negative events in the future. Following
an expectation-violation approach in psychotherapy (see Craske
et al., 2014), depressed patients should be encouraged to expose
themselves to situations that challenge these expectations, and to
focus their attention on whether the negative expectations occur,
or whether expectations are violated. A similar approach could be
used for patients suffering from psychosis. Eventually supported
by antipsychotic drug treatment, patients could be encouraged
to expose themselves to situations that allow checking negative
expectations, and to experience positive interactions. Recent ﬁnd-
ings conﬁrm signiﬁcant incremental effects of such psychological
interventions in addition to pharmacotherapy in psychosis (Lincoln
et al., 2012; Moritz et al., 2014).
Beyond this disorder-speciﬁc expectation modiﬁcation
approach, further interventions should be used in parallel to
drug treatments. Physical activity has a proven clinical beneﬁt in
depression (Cooney et al., 2014; Cooney et al., 2013), and seems
to reduce the risk of side effect development in psychosis. Treat-
ment environments should also include adaptations of “enriched
60 W.  Rief et al. / Neuroscience and Biobehavioral Reviews 60 (2016) 51–64
Fig. 3. Environmental inﬂuences can inverse SSRI effects. Exposure to stress induces an anhedonic behavioral phenotype (“depression-like behavior”) as indicated by
reduced saccharin preference. When combining ﬂuoxetine treatment with environmental enrichment, ﬂuoxetine-treated mice showed a signiﬁcantly higher preference for
the  saccharin solution compared to control mice, indicating an amelioration of the depression-like phenotype. (left: upper line). However, when stress was imposed during
ﬂuoxetine treatment, ﬂuoxetine-treated mice showed a faster and more marked reduction of preference for the saccharin solution compared to control mice, indicating a
worsening of the depression-like phenotype (right: lower line). (From Branchi et al., 2013).
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nvironment” conditions, particularly in depression. More gener-
lly, environmental enrichment and physical activity can enhance
ognitive function, thus contributing to the improvement of other
ymptoms of depression and psychosis (Pang and Hannan, 2013).
he neurophysiological effects of learning are well-known, and
hould be systematically used after drug treatment starts. These
rocesses are able to interact with pharmacologically induced
ffects on brain actions, and can steer them into the right direction
see Table 2).
0. Recommendations for clinical trial design
The ability of a trial to detect the potential of a new drug strongly
epends on whether the protocol fully controls all the factors that
nﬂuence treatment success. If expectations, learning processes,
nd other environmental inﬂuences are not controlled, these vari-
bles can interact beneﬁcially with the pharmacokinetics in one
atient, but these interactions of context factors with psychotropic psychopharmacological interventions.
agents can be detrimental in another patient, thus contributing sub-
stantially to large variations in treatment efﬁciency. All treatment
arms should therefore control these effects as much as possible. The
assessment of patient expectancies (e.g., whether to attend study
visits) can be adjusted for statistically and may  be considered in
imputation procedures, which can increase the estimated group
differences between treatment conditions (Rabideau et al., 2014).
At least one treatment arm of clinical trials should aim to optimize
all of these inﬂuences, to provide information about the maximal
efﬁciency that is possible in a speciﬁc clinical condition. While in
the past it was assumed that these effects might be additive, more
and more evidence shows that these trajectories can interact, which
invites more complex study designs for clinical trials. However,
considering these interactions switches the focus from develop-
ing drugs as an environment-independent stand-alone treatment
to drugs that optimize the interaction with behavior change, and
drugs that amplify learning, expectation modiﬁcation and further
positive environmental stimulation processes.
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Table  2
Recommendations of Drug × Environment Interactions for clinical practice and clin-
ical trial design.
(a) Recommendations for clinical practice
•  Education regarding up-to-date pathophysiological and therapeutic
concepts of a disease, regarding a treatment’s mechanism of action,
estimated treatment onset and bio-psycho-social interactions. Remind
patients of these concepts throughout the therapy.
• Motivate, plan, initiate and support positive social interactions in the
weeks following medication onset.
•  Encourage and support regular physical activities in general (especially
during antipsychotic treatments).
•  Recommend physical activity to cope with symptoms and side effects of
treatment.
•  Analyze disorder-speciﬁc expectations (e.g., fears, catastrophizing
cognitions), and encourage exposure to test these expectations
(expectation-violation approach; e.g., exposure therapy of CBT).
•  Involve the patient in the decision whether a pharmacological or
non-pharmacological approach is taken (shared decision-making).
Pharmacological approaches should always be combined with
non-pharmacologial approaches optimizing environmental inﬂuences (see
above) (e.g., CBT).
• Exploit placebo mechanisms, e.g.,
- Assess patient’s prior treatment experiences, as well as treatment and
outcome expectations, and try to optimize them accordingly.
-  Consider the option of open-label placebo treatments for mild to
moderate forms of depression (Schedlowski et al., 2015).
-  Ask the patient to speciﬁcally pay attention to the drug intake and to
combine drug intake (usually a pill) with distinct sensory or contextual
experiences (e.g., drinking a particular juice, or sitting in a particular chair,
etc.) to facilitate conditioned pharmacological responses.
(b) Recommendations for clinical trial design
•  The major basis for trial sensitivity is the control of any
non-pharmacological inﬂuencing factors!
• Assay sensitivity is always associated with ascertainment quality. Use
systematic and standardized instruments to ascertain not only drug
efﬁcacy, but also contextual inﬂuences and side effect assessments.
• Veriﬁcation of comparability of prior treatment experiences and outcome
expectancies between patients in different treatment arms.
• Assessment of social and environmental factors and of physical activities
that can inﬂuence treatment outcome.
•  Use of these variables to improve statistical analyses of clinical trials (e.g.,
imputation methods; control of covariates).
•  If possible, try to apply a standardized protocol that ensures a)
comparability of physical activity, social inﬂuences, and other stimulating
environmental inﬂuences, and that ensures b) effects steering
pharmacological reactions to positive outcome.
• Try to include at least one study arm that attempts to optimize the
interaction of pharmacological and context factors, to receive an estimate
about the full potential of the treatment plan, but note that assay
sensitivity is higher if patients believe that the chance to be in a placebo
group is 50% (Sinyor et al., 2010). For further recommendations to improve
assay sensitivity see Enck et al. (2013).
•  Development of new drugs should focus on drugs that improve
learning/neuroplasticity.
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depression in primary care. Cochrane Database System. Rev. 3, http://dx.doi.
org/10.1002/14651858.CD007954 (John Wiley & Sons Ltd.).1. Limitations
The above postulated models should be considered as hypothe-
es based on experimental observations and inferences from
andomized-clinical trials that require further validation in a clin-
cal care environment. We  did not aim to summarize the existing
iterature comprehensively; rather we aimed to bring together dif-
erent strands of research (neuroplasticity of psychotropic drugs;
lacebo mechanisms; neurobiology of context/environmental
nﬂuences). Finally, results on neuroplastic processes must be inter-
reted with caution. Their functional relevance remains unclear,
nless behavioral data are included in the studies. An increase of
eurons does not automatically imply an improvement of func-
ionality, but could also indicate an increase of chaotic information
rocessing. This could explain why haloperidol reduces brain con-
ectivity, yet improves the clinical syndrome of schizophrenia
Gass et al., 2013). However, to develop healthy brain functions,avioral Reviews 60 (2016) 51–64 61
brain plasticity processes steered in a helpful direction still seem
to be the way of treatment choice.
While traditional understanding postulated additivity of
pharmacological effects and placebo/environmental effects, the
conclusions of this paper favor models that also consider complex
interactions between inﬂuencing factors. The interactions of these
different factors can further amplify and hamper positive and neg-
ative effects. Moreover, some of these effects could be additionally
subject to ceiling effects. There is some evidence that antidepres-
sant treatment does not further enhance the beneﬁcial effects of
environmental enrichment on a neurobiological level, indicating
that antidepressant treatment and environmental enrichment both
are effective through the same neurobiological pathways, includ-
ing the ones involved in adult neurogenesis (Possamai et al., 2015;
Simpson et al., 2012; Simpson and Kelly, 2012). Current “western”
environments might offer sufﬁcient physical enrichment, yet other
aspects mentioned above (e.g., social contacts) could be further
optimized to support treatment improvements.
Issues relating to the timeline of these interactions are unclear.
Are the effects of positive context stimulation similar, if they occur
the ﬁrst day after drug onset, or if they occur 2 weeks later? These
aspects deserve further investigation.
Despite these shortcomings, there is strong evidence to aban-
don simplistic, monomechanistic models of drug actions for mental
disorders. Negative expectations about drug efﬁciency, anxious
expectations of side effects, low physical activity and low external
stimulation can interact with drug effects and result in poor out-
come; positive expectations, social support and stimulating context
factors can amplify positive drug effects and contribute to excellent
outcomes. The consideration of these complex drug x environment
interactions offers new pathways to improve drug efﬁciency, new
perspectives on drug innovations, and impetus to develop more
sophisticated treatment decisions and treatment schemata.
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